MDL 101986

Drug Profile

MDL 101986

Latest Information Update: 17 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aventis
  • Class Osteoporosis therapies
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Postmenopausal osteoporosis

Most Recent Events

  • 22 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma
  • 15 Nov 1999 Preclinical data have been added to the pharmacodynamics section
  • 16 Feb 1999 Preclinical development for Breast cancer in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top